Evenity (Romosozumab) Cost vs. Alternatives: A Full Class Comparison

How Romosozumab Works: The Sclerostin Mechanism

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a glycoprotein secreted by osteocytes that normally puts the brakes on bone formation. By blocking sclerostin, romosozumab activates the Wnt signaling pathway in osteoblasts, rapidly accelerating new bone deposition while simultaneously reducing bone resorption for a limited window.

Why Dual Action Matters

No other approved osteoporosis drug replicates this dual mechanism. Bisphosphonates and denosumab are purely anti-resorptive: they slow bone breakdown but do not build new bone. Teriparatide and abaloparatide are anabolic (they stimulate osteoblasts), but they also increase resorption markers over time. Romosozumab's anabolic window is strongest during the first 6 months; by month 12, the bone-formation signal attenuates, which is why the FDA limits treatment to 12 monthly doses [1].

Bone Density Gains in Context

In the FRAME trial (N=7,180), romosozumab increased lumbar spine BMD by 13.3% at 12 months vs. 0.0% for placebo [2]. That magnitude of gain in one year exceeds what teriparatide achieves in 18 to 24 months of daily injections. This rapid BMD accrual is the primary clinical rationale for choosing romosozumab despite its higher price tag.

Evenity Pricing: What the 12-Month Course Actually Costs

At wholesale acquisition cost, a single monthly dose of Evenity (two prefilled syringes totaling 210 mg) runs approximately $1,825 to $2,200, depending on the distributor. Twelve doses put the total course between $22,000 and $26,000 before insurance adjustments.

Out-of-Pocket Variability

Medicare Part B covers Evenity as a physician-administered injectable, but beneficiaries typically owe 20% coinsurance after the Part B deductible, translating to $4,400 to $5,200 out of pocket for the full year without supplemental coverage. Commercial plans vary widely. Amgen offers a copay assistance program that can reduce costs to as little as $5 per dose for eligible commercially insured patients [3].

The Hidden Second-Year Cost

Because romosozumab must be followed by an antiresorptive to preserve BMD gains, total treatment cost should include the transition drug. Adding a year of denosumab ($6,000 to $7,800 WAC/year) or generic alendronate (~$120/year) changes the two-year economic picture substantially.

Head-to-Head Efficacy: ARCH Trial Results

The ARCH trial (N=4,093) is the only completed study comparing romosozumab directly to an active comparator (oral alendronate) rather than placebo [4]. Patients received romosozumab 210 mg monthly or alendronate 70 mg weekly for 12 months, then both groups transitioned to open-label alendronate.

Vertebral Fracture Reduction

At 24 months (12 months of romosozumab followed by 12 months of alendronate vs. 24 months of alendronate), romosozumab-to-alendronate reduced new vertebral fractures by 48% (6.2% vs. 11.9%; P<0.001) [4]. That is a number needed to treat (NNT) of approximately 18 over two years.

Non-Vertebral and Hip Fractures

Clinical (non-vertebral) fractures dropped by 19% in the romosozumab-first group (HR 0.81, 95% CI 0.66 to 0.99). Hip fractures specifically fell by 38% (HR 0.62, 95% CI 0.42 to 0.92) [4]. These hip fracture data are particularly relevant given that hip fractures carry a 20% one-year mortality rate in patients over age 65 [5].

The Cardiovascular Signal

ARCH also surfaced a cardiovascular imbalance: adjudicated major adverse cardiac events (MACE) occurred in 2.5% of romosozumab patients vs. 1.9% of alendronate patients over the treatment period [4]. This finding prompted the FDA's boxed warning and limits romosozumab's use in patients with a recent MI or stroke within the preceding year. The FRAME placebo-controlled trial did not show the same signal, so the clinical significance remains debated. The Endocrine Society's 2020 guideline recommends a cardiovascular risk assessment before prescribing [6].

Cost Comparison Table: Romosozumab vs. Every Major Alternative

The following comparison captures approximate annual WAC, route, frequency, and fracture-reduction evidence for each drug in the osteoporosis treatment class.

| Drug (Brand) | Annual WAC | Route | Frequency | Key Fracture Data | |---|---|---|---|---| | Romosozumab (Evenity) | $22,000 to $26,000 (12-mo course) | SC injection | Monthly x 12 | 48% vertebral reduction vs. Alendronate (ARCH) [4] | | Denosumab (Prolia) | $6,000 to $7,800 | SC injection | Every 6 months | 68% vertebral reduction vs. Placebo at 3 yr (FREEDOM) [7] | | Teriparatide (Forteo) | $36,000 to $42,000 | SC injection | Daily x 24 months | 65% vertebral reduction vs. Placebo (Neer et al.) [8] | | Abaloparatide (Tymlos) | $24,000 to $28,000 | SC injection | Daily x 18 months | 86% vertebral reduction vs. Placebo (ACTIVE) [9] | | Zoledronic acid (Reclast) | $1,200 to $1,800 | IV infusion | Once yearly | 70% vertebral reduction vs. Placebo at 3 yr (HORIZON) [10] | | Alendronate (generic) | $100 to $200 | Oral tablet | Weekly | 47% vertebral reduction vs. Placebo (FIT) [11] |

Reading the Numbers Carefully

Direct cross-trial comparison is unreliable because trial populations, follow-up durations, and comparators differ. Romosozumab's ARCH result (48% vs. Active alendronate) is harder to achieve than placebo-controlled reductions. A 48% relative risk reduction against an already-effective drug signals a larger absolute treatment effect than the percentage alone suggests.

When Cost per Fracture Prevented Favors Evenity

A 2021 cost-effectiveness analysis published in the Journal of Bone and Mineral Research modeled the romosozumab-to-denosumab sequence and found an incremental cost-effectiveness ratio (ICER) of approximately $47,000 per quality-adjusted life year (QALY) gained vs. Alendronate alone in women aged 70+ with T-scores below -3.0 and prior vertebral fracture [12]. At a willingness-to-pay threshold of $100,000/QALY, the sequence was cost-effective in this high-risk subgroup. For lower-risk patients (T-score -2.5 to -3.0, no prior fracture), the ICER exceeded $150,000/QALY, suggesting bisphosphonates or denosumab remain the better economic choice [12].

Who Should Get Romosozumab Over Cheaper Alternatives

The 2020 American Association of Clinical Endocrinology (AACE) guideline and the Endocrine Society both position romosozumab as a first-line option specifically for patients at "very high" fracture risk [6]. That category includes postmenopausal women with a T-score at or below -3.0, those with a recent osteoporotic fracture (within the past 2 years), or patients who fracture while on existing antiresorptive therapy.

The Sequential Strategy

Current evidence strongly favors starting with an anabolic agent (romosozumab, teriparatide, or abaloparatide) and then transitioning to an antiresorptive, rather than the reverse. The VERO trial showed that teriparatide followed by denosumab produced greater BMD gains than denosumab followed by teriparatide [13]. Romosozumab followed by denosumab produced the largest 24-month lumbar spine BMD gains recorded in any osteoporosis trial sequence: approximately 17 to 18% [2].

Patients Who Should Not Receive Evenity

The boxed warning excludes patients who have had an MI or stroke within the past 12 months. Patients with unexplained hypocalcemia, those with Paget's disease, or anyone with open epiphyses (pediatric populations) are also contraindicated. For patients with moderate cardiovascular risk, the prescriber must weigh the fracture-reduction benefit against the uncertain cardiac signal seen in ARCH [4].

Denosumab (Prolia) as the Primary Alternative

Denosumab is a RANK ligand inhibitor given as a 60 mg subcutaneous injection every 6 months. At $6,000 to $7,800 per year, it costs roughly one-third of romosozumab on a per-year basis, and treatment duration is indefinite.

Efficacy Profile

The FREEDOM trial (N=7,868) demonstrated a 68% reduction in vertebral fractures, 40% reduction in hip fractures, and 20% reduction in non-vertebral fractures vs. Placebo over 3 years [7]. Ten-year extension data showed sustained fracture reduction and progressive BMD gains with continued dosing [14].

The Discontinuation Problem

Stopping denosumab triggers a rapid rebound in bone turnover markers and accelerated bone loss. Multiple vertebral fractures have been reported within 7 to 12 months of discontinuation. The FDA issued a drug safety communication in 2022 warning against abrupt cessation [15]. Patients must transition to a bisphosphonate before stopping denosumab. This lifelong commitment compounds the total cost well beyond the initial per-year figure.

Denosumab After Romosozumab

In the DATA-Switch study, patients who received romosozumab for 12 months followed by denosumab for 12 months achieved lumbar spine BMD increases of approximately 17.5%, higher than any single-agent strategy [16]. This romosozumab-to-denosumab sequence is now considered the most aggressive evidence-based regimen for very-high-risk patients.

Teriparatide and Abaloparatide: The Other Anabolic Options

Teriparatide (Forteo) and abaloparatide (Tymlos) both activate the PTH1 receptor to stimulate osteoblast activity. They require daily self-injection and carry lifetime use limits (24 months for teriparatide, 18 months for abaloparatide) based on osteosarcoma findings in rat studies, though no confirmed human cases have been attributed to either drug.

Cost Comparison With Romosozumab

Teriparatide runs $36,000 to $42,000 for a 24-month course. Generic teriparatide became available in late 2023, bringing potential costs down, though biosimilar pricing has not yet dropped as sharply as expected. Abaloparatide costs $24,000 to $28,000 for 18 months. Romosozumab's 12-month course at $22,000 to $26,000 is actually cheaper than branded teriparatide and comparable to abaloparatide when measured per month of therapy.

Efficacy Differences

No head-to-head trial directly compares romosozumab to teriparatide or abaloparatide. Indirect comparisons using network meta-analyses suggest romosozumab produces faster BMD gains at the lumbar spine, while abaloparatide may have a modest advantage at the total hip [17]. All three anabolic agents reduce vertebral fractures significantly compared to placebo; the clinical differences between them are smaller than the gap between any anabolic and an antiresorptive-only approach.

Bisphosphonates: The Budget Backbone

Generic alendronate at $100 to $200 per year and zoledronic acid at $1,200 to $1,800 per annual infusion remain the cost-effective workhorses for moderate-risk osteoporosis.

When Bisphosphonates Are Enough

For patients with T-scores between -2.5 and -3.0, no prior fragility fracture, and a 10-year FRAX hip fracture probability below 3%, oral bisphosphonates are first-line per AACE 2020 guidelines [18]. The FIT trial showed alendronate reduced vertebral fractures by 47% over three years in women with existing vertebral fractures [11]. Zoledronic acid's HORIZON trial (N=7,765) showed a 70% reduction in vertebral fractures and 41% reduction in hip fractures over three years [10].

When Bisphosphonates Fall Short

Patients who fracture on bisphosphonate therapy, those with very low T-scores (below -3.5), or those who cannot tolerate oral dosing (esophageal stricture, inability to remain upright for 30 minutes) should be moved to an anabolic agent or denosumab. Atypical femoral fractures and osteonecrosis of the jaw are rare but real risks with long-term bisphosphonate use (incidence approximately 3 to 50 per 100,000 patient-years for atypical fractures depending on duration) [19].

Insurance Coverage and Access Strategies

Evenity's high cost means prior authorization is nearly universal. Most commercial payers and Medicare require documentation of: (1) a DXA-confirmed T-score at or below -2.5, (2) high fracture risk by FRAX or prior fracture history, and (3) in many cases, failure or intolerance of at least one bisphosphonate.

Medicare Part B

Because Evenity is administered via subcutaneous injection by a healthcare provider, it falls under Part B's "incident to" billing. The CMS average sales price (ASP) plus 6% reimbursement model applies. Patients with Medigap Plan F or G will have minimal out-of-pocket cost. Those without supplemental insurance face the 20% coinsurance burden.

Commercial Insurance

Step therapy requirements are common. Many payers mandate a 12-month trial of alendronate or risedronate before approving Evenity. Amgen's Evenity copay card covers up to $15,000 per year for eligible commercially insured patients, which can substantially close the cost gap.

The Appeal Process

If denied, the prescriber should emphasize the patient's "very high risk" classification per AACE/Endocrine Society criteria and cite ARCH trial fracture reduction data. Peer-to-peer review with the payer's medical director, armed with the ARCH publication and AACE position statement, overturns approximately 60 to 70% of initial denials according to published access surveys [20].

Practical Prescribing: The Romosozumab Decision Algorithm

Assess 10-year fracture probability using FRAX with BMD input. If hip fracture probability exceeds 3% or major osteoporotic fracture probability exceeds 20%, the patient qualifies for pharmacotherapy. Within that group, stratify further.

For patients with T-score at or below -3.0, prior vertebral fracture, or fracture on existing therapy: romosozumab 210 mg SC monthly for 12 doses, followed by denosumab 60 mg SC every 6 months, is the highest-efficacy sequence. Confirm no MI or stroke within the past year before initiating.

For patients with moderate risk (T-score -2.5 to -3.0, no prior fracture): start with alendronate 70 mg weekly or zoledronic acid 5 mg IV annually. Reserve romosozumab for those who fracture on therapy or show continued BMD decline at 2-year DXA follow-up.

Recheck DXA 12 months after completing the romosozumab course to confirm expected BMD gains (target: 10% or greater increase at lumbar spine). If gains fall below 5%, evaluate for secondary causes of osteoporosis including vitamin D deficiency, celiac disease, or hyperparathyroidism [6].